Pacira BioSciences, Inc. (PCRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pacira BioSciences, Inc. stock (PCRX) is currently trading at $23.49. Pacira BioSciences, Inc. PE ratio is 138.19. Pacira BioSciences, Inc. PS ratio (Price-to-Sales) is 1.31. Analyst consensus price target for PCRX is $29.00. WallStSmart rates PCRX as Sell.
- PCRX PE ratio analysis and historical PE chart
- PCRX PS ratio (Price-to-Sales) history and trend
- PCRX intrinsic value — DCF, Graham Number, EPV models
- PCRX stock price prediction 2025 2026 2027 2028 2029 2030
- PCRX fair value vs current price
- PCRX insider transactions and insider buying
- Is PCRX undervalued or overvalued?
- Pacira BioSciences, Inc. financial analysis — revenue, earnings, cash flow
- PCRX Piotroski F-Score and Altman Z-Score
- PCRX analyst price target and Smart Rating
Pacira BioSciences, Inc.
📊 No data available
Try selecting a different time range
PCRX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Pacira BioSciences, Inc. (PCRX)
PCRX trades 1894% above its Graham fair value of $1.09, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Pacira BioSciences, Inc. (PCRX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Pacira BioSciences, Inc. (PCRX) Key Strengths (3)
118.08% of shares held by major funds and institutions
Paying $1.31 for every $1 of annual revenue
Trading at 1.29x book value, attractively priced
Supporting Valuation Data
Pacira BioSciences, Inc. (PCRX) Areas to Watch (7)
Losing money on operations
Earnings declining -88.40%, profits shrinking
Very low returns on shareholder equity
Very expensive relative to growth, significant premium
Very thin margins, barely profitable
Modest revenue growth at 5.10%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Pacira BioSciences, Inc. (PCRX) Detailed Analysis Report
Overall Assessment
This company scores 40/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.7/10) while 7 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, Price/Book. Valuation metrics including Price/Sales (1.31), Price/Book (1.29) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, EPS Growth, Return on Equity. Some valuation metrics including PEG Ratio (11.21) suggest expensive pricing. Growth concerns include Revenue Growth at 5.10%, EPS Growth at -88.40%, which may limit upside. Profitability pressure is visible in Return on Equity at 0.96%, Operating Margin at -1.17%, Profit Margin at 0.97%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 0.96% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 5.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PCRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PCRX's Price-to-Sales ratio of 1.31x trades at a deep discount to its historical average of 12.96x (5th percentile). The current valuation is 98% below its historical high of 59.4x set in Dec 2013, and 47% above its historical low of 0.89x in Sep 2024.
Compare PCRX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Pacira BioSciences, Inc. (PCRX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Pacira BioSciences, Inc. is a mature, profitable business with steady cash generation. Revenue reached 726M with 5% growth year-over-year. Profit margins are strong at 97.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 96.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 43M in free cash flow and 44M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Valuation compression risk at a P/E of 138.2x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Pacira BioSciences, Inc..
Bottom Line
Pacira BioSciences, Inc. is a well-established business delivering consistent profitability with 97.0% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(26 last 3 months)
| Insider | Type | Shares |
|---|---|---|
HIRAWAT, SAMIT Director | Buy | +39,291 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:27 AM
About Pacira BioSciences, Inc.(PCRX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.